PolarityBio Announces Interim Enrollment Achieved in SkinTE’s Phase III Pivotal Study Interim Analysis Anticipated at end of Q1 2025 SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company developing regenerative tissue products, today...

PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers SALT LAKE CITY, May 20, 2024 (GLOBE NEWSWIRE) -- PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in...

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) -- PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of...